26 February 2016 - Novartis today announced that the United States FDA approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced or metastatic.

For more details, go ro: https://www.novartis.com/news/media-releases/fda-approves-new-indication-novartis-drug-afinitor®-progressive-nonfunctional-gi